NewAmsterdam Pharma (NAMS) Notes Payables (2022 - 2026)

NewAmsterdam Pharma (NAMS) has 5 years of Notes Payables data on file, last reported at $50.2 million in Q1 2026.

• For the quarter ending Q1 2026, Notes Payables rose 113.53% year-over-year to $50.2 million; the trailing twelve-month figure through Mar 2026 stood at $50.2 million (up 113.53% YoY), and the FY2025 full-year result was $57.3 million, up 52.67% from the prior year.
• Notes Payables fell to $50.2 million in Q1 2026, from $57.3 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $57.3 million in Q4 2025 to a low of $4.0 million in Q4 2022.
• A 5-year average of $27.9 million and a median of $23.5 million in 2024 frame the typical range for Notes Payables.
• Across the five-year window, Notes Payables soared 216.99% in 2023 and declined 28.85% in 2025, its largest moves.
• Tracing NAMS's Notes Payables over 5 years: stood at $4.0 million in 2022, then soared by 216.99% to $12.6 million in 2023, then surged by 198.35% to $37.5 million in 2024, then jumped by 52.67% to $57.3 million in 2025, then declined by 12.3% to $50.2 million in 2026.
• Business Quant data shows NAMS's Notes Payables at $50.2 million in Q1 2026, $57.3 million in Q4 2025, and $44.4 million in Q3 2025.